Chia-Hao Kang

Title: Innovations of Chia-Hao Kang in Hepatitis B Therapeutic Vaccines

Introduction

Chia-Hao Kang is a notable inventor based in Hsinchu County, Taiwan. He has made significant contributions to the field of medical science, particularly in the development of therapeutic vaccines for hepatitis B. His innovative work has the potential to impact the treatment of this viral infection.

Latest Patents

Chia-Hao Kang holds a patent for a fusion protein designed for use as a hepatitis B therapeutic vaccine. This patent describes a fusion protein that includes an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, a protein transduction domain, and an antigen comprising a hepatitis B virus X protein deletion mutant. The unique structure of this fusion protein is aimed at enhancing the immune response against hepatitis B.

Career Highlights

Kang's career is marked by his dedication to advancing vaccine technology. His work at Thevax Genetics Vaccine Co., Ltd. has positioned him as a key player in the field of vaccine research and development. His innovative approach to therapeutic vaccines showcases his commitment to improving public health.

Collaborations

Chia-Hao Kang collaborates with esteemed colleagues, including Chia-Mao Wu and Jiun-Ming Wu. These partnerships enhance the research and development efforts at Thevax Genetics Vaccine Co., Ltd., fostering an environment of innovation and scientific inquiry.

Conclusion

Chia-Hao Kang's contributions to hepatitis B therapeutic vaccines exemplify the importance of innovation in medical science. His work not only advances vaccine technology but also holds promise for improving treatment options for patients worldwide.